MS Drug RPC1063 Discovered at TSRI Is Safe and Effective in Phase II Study « New Drug Approvals

MS Drug RPC1063 Discovered at TSRI Is Safe and Effective in Phase II Study « New Drug Approvals:



'via Blog this'

MS Drug RPC1063 Discovered at TSRI Is Safe and Effective in Phase II Study « New Drug Approvals

MS Drug RPC1063 Discovered at TSRI Is Safe and Effective in Phase II Study « New Drug Approvals:



'via Blog this'

R&D productivity: Drug approvals don’t tell the whole story

R&D productivity: Drug approvals don’t tell the whole story

By Zachary Brennan, 28-May-2014

As the number of drug approvals declined between 2012 and 2013 by more than 30%, the value of new therapeutic agent approvals seems to indicate a stronger year than initially thought.

http://www.in-pharmatechnologist.com/Processing/R-D-productivity-Drug-approvals-don-t-tell-the-whole-story

New method for uncovering side effects before a drug hits the market

 

New method for uncovering side effects before a drug hits the market

 http://www.sciencedaily.com/releases/2013/01/130102140516.htm

Side effects are a major reason that drugs are taken off the market and a major reason why patients stop taking their medications, but scientists are now reporting the development of a new way to predict those adverse reactions ahead of time. The report on the method, which could save patients from severe side effects and save drug companies time and money, appears in ACS' Journal of Chemical Information and Modeling.

Yoshihiro Yamanishi and colleagues explain that drug side effects are a major health problem -- the fourth-leading cause of death in the U.S. -- which by some estimates claim 100,000 lives every year. Serious side effects are the main reason why existing drugs must be removed from the market and why pharmaceutical companies halt development of new drugs after investing millions of dollars. Current methods of testing for side effects are costly and inaccurate. That's why the scientists sought to develop a new computer-based approach to predicting possible side effects.

Tackling Taxol

Tackling Taxol

An efficient synthesis of the tricyclic core of Taxol has been developed
Read more

Shire signs monoclonal antibody agreement with arGEN-X

Shire signs monoclonal antibody agreement with arGEN-X
Shire Pharmaceuticals and arGEN-X, a Dutch clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, have agreed a long-term alliance to develop human monoclonal antibodies... SEE AT
http://www.manufacturingchemist.com/news/article_page/Shire_signs_monoclonal_antibody_agreement_with_arGENX/99076/cn48579?dm_i=8EU,2J3KW,9ETTTY,9805Y,1

Tie up with Emcure…..Roche to launch cheaper cancer drugs in India « New Drug Approvals

Tie up with Emcure…..Roche to launch cheaper cancer drugs in India « New Drug Approvals:



'via Blog this'